Neutrolis Inc
Abdul (Hakkim) R has a diverse work experience. Abdul (Hakkim) began their career in 2005 at the Max Planck Institute for Infection Biology, where they worked on Neutrophil Extracellular Traps (NETs) as part of their PhD in Immunology. After completing their PhD in 2010, they joined Harvard Medical School as a Research Fellow, where they focused on identifying innate immune strategies and modeling human disease phenotypes using the genetic model organism C. elegans. Abdul (Hakkim) then transitioned to a role as a Research Associate at Harvard Medical School, where they worked until 2018.
In 2017, Abdul co-founded Neutrolis Inc and served as the Founding CEO until 2020. Abdul (Hakkim) then became the Chairman of the company until 2021, and currently holds the position of Co-President and COO.
Abdul (Hakkim) R's education history began in 2005 when they enrolled at the Max Planck Society to pursue a Doctor of Philosophy (PhD) degree in Microbiology and Immunology. Abdul (Hakkim) dedicated five years to completing their PhD program, and in 2010, they graduated from the Max Planck Society.
After obtaining their PhD, Abdul (Hakkim) R continued their academic journey by joining Harvard Medical School as a Research Fellow in Immunology. Abdul (Hakkim) embarked on this new role in 2010 and remained at the institution for five years until 2015.
Overall, Abdul (Hakkim) R's education history showcases their commitment to scientific research and their expertise in the fields of Microbiology and Immunology.
This person is not in any teams
This person is not in any offices
Neutrolis Inc
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. Although NETs represent one of the most important immunology discoveries in the past 20 years, there is no therapyon the market that effectively targets and removes NETs. Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that effectively removes NETs and halt their pathologic effects on end-organs. Neutrolis has a strong patent portfolio for new molecular entity and method of use. The lead molecule, NTR-441, is slated to enter clinical trials in 2021.